Ionis Pharmaceuticals Announces Positive Topline Results from Olezarsen Study for Moderate Hypertriglyceridemia

Details

announced positive topline results from the Essence study of olezarsen in patients with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk for atherosclerotic cardiovascular disease (ASCVD). The study met its primary endpoint with a statistically significant reduction in triglyceride levels at 6 months for both the 80 mg and 50 mg monthly doses of olezarsen compared to placebo (p <0.0001). Olezarsen also met all key secondary endpoints, demonstrating a favorable safety and tolerability profile. The study involved nearly 1,500 participants and supports the exposure database for olezarsen, with data from pivotal Phase 3 studies expected in Q3 2025.

Items reported

Exhibits (1)

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.